Nature Publishing Group, publisher of Nature, and other science journals and reference works NATURE.COM NATURE NEWS NATUREJOBS NATUREEVENTS ABOUT NPG
Help Nature.com site index  
Bone Marrow Transplantation
SEARCH     advanced search my account e-alerts subscribe register
Journal home
Advance online publication
Current issue
Archive
Press releases
For authors
For referees
Contact editorial office
About the journal
For librarians
Subscribe
Advertising
naturereprints
Contact NPG
Customer services
Site features
NPG Subject areas
Access material from all our publications in your subject area:
Biotechnology Biotechnology
Cancer Cancer
Chemistry Chemistry
Dentistry Dentistry
Development Development
Drug Discovery Drug Discovery
Earth Sciences Earth Sciences
Evolution & Ecology Evolution & Ecology
Genetics Genetics
Immunology Immunology
Materials Materials Science
Medical Research Medical Research
Microbiology Microbiology
Molecular Cell Biology Molecular Cell Biology
Neuroscience Neuroscience
Pharmacology Pharmacology
Physics Physics
Browse all publications
 
April (2) 2002, Volume 29, Number 8, Pages 681-682
Table of contents    Previous  Abstract  Next   Full text  PDF
Allografting
Transfusion-dependent congenital dyserythropoietic anemia type I successfully treated with allogeneic stem cell transplantation
M Ayas, A Al-Jefri, A Baothman, M Al-Mahr, M M Mustafa, S Khalil, M Karaoui and H Solh

Department of Pediatric Hematology Oncology, King Faisal Specialist Hospital and Research Center (KFSH&RC), Riyadh, Saudi Arabia

Correspondence to: Dr M Ayas, Department of Oncology, King Faisal Specialist Hospital and Research Center, MBC 53, PO Box 3354, Riyadh 11211, Saudi Arabia

Abstract

Until recently, therapy for patients with severe congenital dyserythropoietic anemia (CDA) has been limited to blood transfusions and chelation therapy. Three children with transfusion-dependent CDA type I underwent allogeneic stem cell transplantation (SCT) from matched sibling donors. Conditioning was with cyclophosphamide 50 mg/kg/day for 4 days, busulphan 4 mg/kg/day for 4 days, and antithymocyte globulin (ATG) 30 mg/kg for four doses pre-SCT. All patients engrafted and are alive, and transfusion independent. To our knowledge, this is the first report of successful SCT in the management of CDA type I.

Bone Marrow Transplantation (2002) 29, 681-682. DOI: 10.1038/sj/bmt/1703526

Keywords

stem cell transplantation; dyserythropoietic anemia; congenital anemia; ineffective erythropoiesis; interferon

Received 16 October 2001; accepted 24 January 2002
April (2) 2002, Volume 29, Number 8, Pages 681-682
Table of contents    Previous  Abstract  Next   Full text  PDF
Privacy Policy © 2002 Nature Publishing Group